Missing Script

Get updates

MS-N122 · Supportive care · Human evidence · Appraised 24 October 2026

Can acupuncture begun during head-and-neck radiotherapy reduce later xerostomia?

Evidence at a glance

  • Evidence label: Suggestive evidence; prevention data are not definitive
  • Benefit: One randomized trial in nasopharyngeal cancer found fewer dry-mouth symptoms and higher salivary flow during and after radiotherapy.
  • Certainty: Low-to-moderate confidence because the comparator was usual care without sham acupuncture and six-month attrition was substantial.
  • Risk: Needling during radiotherapy requires attention to infection, bleeding and irradiated tissue.

What was studied

Population and design: 86 adults receiving radiotherapy for nasopharyngeal carcinoma were randomized: 40 to acupuncture and 46 to standard care.

Studied regimen: Acupuncture three times weekly during radiotherapy; no sham procedure was used.

What the evidence found

The relative risk of clinically meaningful xerostomia symptoms was 0.63 (95% CI 0.45–0.87) at week 11 and 0.38 (0.19–0.76) at 6 months. Objective salivary-flow measures also favored acupuncture. Five participants died and 19 could not return for the six-month assessment.

How to interpret it

Without an attention-matched sham, expectancy and reporting effects cannot be separated from a specific needling effect. Attrition further weakens the six-month estimate. Modern tissue-sparing radiotherapy remains the central preventive strategy. This is symptom-prevention evidence, not tumor-control evidence.

Practical safety context

Avoid needling through irradiated, infected or fragile skin. Coordinate around neutropenia, thrombocytopenia, anticoagulants and altered head-and-neck anatomy. New or worsening dry mouth also deserves evaluation for dehydration, infection, dental risk and medication effects.

Questions for the care team

  • Is the symptom or complication being caused by something that needs conventional treatment first?
  • Would blood counts, anticoagulants, infection risk, surgery, radiation effects or implanted devices change whether this is safe?
  • What outcome will we track, and when should we stop if it is not helping?

Funding and conflicts

The trial reported grant support from the US National Cancer Institute and Chinese partners; conflict information is in the full text.

Sources

Last literature search: 24 October 2026. Record appraisal: 24 October 2026. This page is educational and does not replace individualized medical advice. Symptom improvement must not be interpreted as evidence of tumor response, delayed recurrence or longer survival.